Prosecution Insights
Last updated: October 01, 2026

Examiner: RONEY, CELESTE A

Tech Center 1600 • Art Units: 1612 1615 1618

This examiner grants 63% of resolved cases

Analysis

Celeste A. Roney serves in Art Unit 1612 of Tech Center 1600. With 771 resolved cases, the examiner has established an allowance rate of 62.8 percent. This volume of cases provides a robust statistical foundation for understanding the examiner's prosecution tendencies and decision-making patterns. The 62.8 percent allowance rate indicates a moderate level of difficulty, requiring well-supported arguments to secure a patent grant.

The data indicates an interview lift of 17.5 percent. This positive lift suggests that applicants may find value in requesting interviews to clarify technical points or negotiate claim language, as these interactions are associated with higher allowance probabilities. The 17.5 percent increase in success rate highlights the examiner's willingness to engage in productive dialogue. For practitioners, this means that an interview should be viewed as a standard part of the prosecution strategy rather than an exceptional measure.

The median days to allowance for this examiner is 1104. This timeline offers a predictable window for the duration of the examination process, helping applicants manage their expectations for patent issuance. The 1104-day median is a key metric for strategic planning, especially when coordinating patent filings with product launches or funding rounds. It provides a realistic view of the time commitment required to navigate the 1612 Art Unit's requirements.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

62.8%
Allow Rate
+2.8% vs TC avg
818
Total Applications
+17.5%
Interview Lift
1104
Avg Prosecution Days
Based on 771 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
3.9%
§102 Novelty
55.5%
§103 Obviousness
19.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18563898 HALLUCINOGEN-FATTY ACID COMBINATION Non-Final OA Mindset Pharma Inc.
18182733 LIPID COMPOSITION Final Rejection FUJIFILM Corporation
17917233 MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS Final Rejection The Regents of the University of California
18283406 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS Non-Final OA The Board of Regents of the University of Texas System
17497517 METHODS AND SYSTEMS FOR DETECTING PSYCHOTIC DISORDERS ASSOCIATED WITH SEROTONIN RECEPTOR DEFICIENCIES Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
19066812 HAIR TREATMENT COMPOSITION Non-Final OA L'OREAL
18716488 COMPOSITION FOR KERATIN FIBERS Non-Final OA L'Oreal
18731085 COMPOSITIONS AND METHODS FOR CARING FOR KERATIN MATERIALS Final Rejection L'Oreal
18690391 MAKEUP KIT COMPRISING AN AQUEOUS MAKEUP COMPOSITION AND A CONTINUOUS OILY-PHASE FIXING COMPOSITION WITH A HYDROPHOBIC FILM-FORMING POLYMER Final Rejection L'OREAL
18084403 COMPOSITIONS AND METHODS FOR REMOVING COLOR FROM HAIR Non-Final OA L'Oreal
18252597 COMPOUNDS FOR THE DETECTION OF HEME OXYGENASE 1 (HO-1), AND METHODS AND USES INVOLVING THE SAME Non-Final OA IMPERIAL COLLEGE INNOVATIONS LIMITED
18996093 LOADED EXTRACELLULAR VESICLE Non-Final OA Oxford University Innovation Limited
18292042 METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS Final Rejection Alexion Pharmaceuticals, Inc.
18503474 USES OF BUPIVACAINE MULTIVESICULAR LIPOSOMES AS STELLATE GANGLION BLOCK FOR TREATING ANXIETY DISORDERS AND TRAUMATIC BRAIN INJURY Final Rejection Pacira Pharmaceuticals, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month